35,657 Becton, Dickinson and Company $BDX Shares Purchased by E. Ohman J or Asset Management AB

Key Points

• Institutional interest increased: E. Öhman Jor Asset Management AB boosted its Becton, Dickinson and Company position by 349.4%, purchasing 35,657 additional shares to hold 45,863 shares valued at $8.2 million. Institutional investors and hedge funds collectively own 86.97% of BDX.
• Analyst sentiment remains cautious: Analysts have an average “Hold” rating and a consensus price target of $185.07, despite target increases from several firms. The stock recently opened at $200.21, near its 12-month high of $200.47.
• Quarterly results exceeded expectations: BD reported earnings of $3.23 per share versus the $3.14 consensus estimate and revenue of $4.98 billion, up 5.4% year over year. The company also declared a quarterly dividend of $1.05 per share, representing a 2.1% annualized yield.

E. Ohman J or Asset Management AB raised its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 349.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,863 shares of the medical instruments supplier's stock after purchasing an additional 35,657 shares during the period. E. Ohman J or Asset Management AB's holdings in Becton, Dickinson and Company were worth $8,209,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of BDX. SBI Securities Co. Ltd. boosted its holdings in shares of Becton, Dickinson and Company by 48.8% during the third quarter. SBI Securities Co. Ltd. now owns 1,820 shares of the medical instruments supplier's stock worth $326,000 after purchasing an additional 597 shares during the last quarter. Pinnacle Bancorp Inc. lifted its position in Becton, Dickinson and Company by 102.3% during the third quarter. Pinnacle Bancorp Inc. now owns 445 shares of the medical instruments supplier's stock worth $80,000 after buying an additional 225 shares during the period. Cardinal Capital Management boosted its stake in Becton, Dickinson and Company by 8.3% in the 3rd quarter. Cardinal Capital Management now owns 36,780 shares of the medical instruments supplier's stock worth $6,584,000 after buying an additional 2,810 shares during the last quarter. Foster Victor Wealth Advisors LLC boosted its stake in Becton, Dickinson and Company by 1.4% in the 3rd quarter. Foster Victor Wealth Advisors LLC now owns 61,476 shares of the medical instruments supplier's stock worth $11,726,000 after buying an additional 839 shares during the last quarter. Finally, Vest Financial LLC grew its holdings in Becton, Dickinson and Company by 14.9% in the 3rd quarter. Vest Financial LLC now owns 356,140 shares of the medical instruments supplier's stock valued at $63,749,000 after buying an additional 46,239 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company's stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Feld sold 165 shares of the business's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 6,906 shares of company stock valued at $1,265,855. Corporate insiders own 0.40% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BDX. Piper Sandler upped their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Friday, August 7th. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a "buy" rating and a $190.00 price target for the company. Bank of America increased their price target on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a "neutral" rating in a research note on Monday, August 31st. TD Cowen lifted their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a "hold" rating in a report on Wednesday, August 5th. Finally, Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $185.07.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $200.21 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $55.16 billion, a price-to-earnings ratio of 14.95, a PEG ratio of 13.10 and a beta of 0.21. The firm's fifty day simple moving average is $185.10 and its 200 day simple moving average is $164.86. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $200.47.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm's quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.